Introduction: Differential diagnosis of parkinsonian disorders can be difficult on clinical grounds, especially in the early stage. Recent advancements in 18-F-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging reveals different patterns of regional glucose metabolism in idiopathic Parkinson's disease (IPD) and atypical parkinsonian syndromes, such as multiple system atrophy (MSA), progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS), which may help differentiating between these conditions.
Purpose: To assess the utility of FDG-PET imaging in differential diagnosis of Parkinsonism in clinical practice.
Methods: FDG-PET was performed in 72 patients with parkinsonism (age 34-80 years) referred to our center by movement disorder specialists. FDG-PET diagnosis was obtained by visual assessment of individual scans combined with voxel-based statistical parametric mapping analysis. FDG-PET diagnosis assigned at the time of imaging was compared with the final clinical diagnosis made by the movement disorder specialists after ≥2 years follow-up.
Results: FDG-PET findings were consistent with IPD in 27, MSA in 18, PSP in 19 and CBS in 2 patients. The final clinical diagnosis was IPD in 29, MSA in 20, PSP in 21 and CBS in 2 patients. Concordance between the FDG-PET and clinical diagnoses was 92% in the overall sample (IPD 93%, MSA 90%, PSP 91% and CBS 100%). The diagnostic accuracy of FDG-PET was 93% for IPD and MSA and 97% for PSP.
Conclusion: FDG-PET may help differentiate between IPD, MSA, PSP and CBS among patients presenting with parkinsonian symptoms, which is important for patient counselling and making early decisions about treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/01616412.2017.1312211 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Reviewing the Diagnostic Performance of 99mTc-TRODAT-1 Imaging in Distinguishing Idiopathic Parkinson's Disease from Parkinson-Plus Syndromes.
World J Nucl Med
December 2024
Department of Neurology, All India Institute of Medical Sciences, Rishikesh, Rishikesh, Uttarakhand, India.
Diagnosing movement disorders can be challenging owing to their similar clinical presentations with other neurodegenerative and basal ganglia disorders, like idiopathic Parkinson's disease (IPD), essential tremors (ET), vascular parkinsonism, multiple system atrophy (MSA), and progressive supranuclear palsy (PSP). Technetium-99m labeled tropane derivative (99mTc-TRODAT-1) imaging can help in diagnosing Parkinson's disease at an early stage to help early initiation of the treatment. The current study aimed to evaluate the role of 99mTc-TRODAT-1 imaging in differentiating IPD and Parkinson-plus syndromes (PPS).
View Article and Find Full Text PDFSingle-nucleus transcriptomics reveals disease- and pathology-specific signatures in α-synucleinopathies.
Brain
November 2024
Neuro-SysMed, Department of Neurology, Haukeland University Hospital, 5021 Bergen, Norway.
α-synucleinopathies are progressive neurodegenerative disorders characterized by intracellular aggregation of α-synuclein, yet their molecular pathogenesis remains unknow. Here, we explore cell-specific changes in gene expression across different α-synucleinopathies. We perform single-nucleus RNA sequencing on nearly 300,000 nuclei from the prefrontal cortex of individuals with idiopathic Parkinson's disease (iPD, n = 20), Parkinson's disease caused by LRRK2 mutations (LRRK2-PD, n = 7), multiple system atrophy (MSA, n = 6) and healthy controls (n = 13).
View Article and Find Full Text PDFAsymmetry in Atypical Parkinsonian Syndromes-A Review.
J Clin Med
September 2024
Department of Neurology, Medical University of Warsaw, 03-242 Warsaw, Poland.
Atypical parkinsonian syndromes (APSs) are a group of neurodegenerative disorders that differ from idiopathic Parkinson's disease (IPD) in their clinical presentation, underlying pathology, and response to treatment. APSs include conditions such as multiple system atrophy (MSA), progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), and dementia with Lewy bodies (DLB). These disorders are characterized by a combination of parkinsonian features and additional symptoms, such as autonomic dysfunction, supranuclear gaze palsy, and asymmetric motor symptoms.
View Article and Find Full Text PDFRadiomics-Guided Deep Learning Networks Classify Differential Diagnosis of Parkinsonism.
Brain Sci
July 2024
School of Life Sciences, Shanghai University, Shanghai 200444, China.
Article Synopsis
- The study proposes a new radiomics-guided deep learning model to improve the differential diagnosis of atypical Parkinsonian syndromes, which can be difficult to distinguish.
- Researchers analyzed data from 1495 subjects, including healthy controls and patients with various Parkinsonian disorders, using F-FDG PET scans to develop and validate the model.
- The results showed that this deep learning approach outperformed traditional methods, achieving high sensitivity rates for diagnosing different types of Parkinson's disease and providing interpretable features linked to biological aspects of the disorders.
microRNA and circRNA in Parkinson's Disease and atypical parkinsonian syndromes.
Adv Clin Chem
September 2023
1st Department of Neurology, Medical School, Aeginition Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP) are atypical parkinsonian syndromes (APS) with various clinical phenotypes and considerable clinical overlap with idiopathic Parkinson's disease (iPD). This disease heterogeneity makes ante-mortem diagnosis extremely challenging with up to 24% of patients misdiagnosed. Because diagnosis is predominantly clinical, there is great interest in identifying biomarkers for early diagnosis and differentiation of the different types of parkinsonism.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!